# Body Adiposity Indices, Adipokines Profile, and CNR1 Polymorphisms in Atypical Phenotypes of Obesity

**Authors:** Simona Georgiana Popa, Loredana Maria Marin, Loredana Maria Dira, Ana Cristina Tudosie, Andreea Loredana Golli

PMC · DOI: 10.3390/metabo16020091 · Metabolites · 2026-01-25

## TL;DR

This study explores atypical obesity types linked to insulin resistance and their metabolic profiles, showing how some obese individuals have better health outcomes than others.

## Contribution

The study identifies distinct metabolic profiles and risk factors for atypical obesity phenotypes, including gender and age differences.

## Key findings

- The ISO phenotype was most common in middle-aged men and had a better metabolic profile than IRO.
- IRNW individuals showed worse glycoregulation and lipid profiles compared to ISNW but similar to IRO.
- IRNW had significantly higher odds of prediabetes compared to ISNW.

## Abstract

Background/Objectives: Insulin-Resistant Normal Weight and Insulin-Sensitive Obesity are atypical cardiometabolic phenotypes whose clinico-biological features, management, and prognosis are a subject of extensive scientific debate. The current study aimed to assess the prevalence of metabolic phenotypes of obesity and to evaluate their association with markers related to diabesity, adipokines profile, and two single nucleotide polymorphisms of CNR1 gene. Methods: We performed a cross-sectional analysis in a random sample of 487 individuals (53.03 ± 13.71 years, 48.3% male) which were classified based on body mass index (</≥25 kg/m2) and insulin resistance (HOMA-IR cut-off value 2.5) as Insulin-Sensitive/Insulin-Resistant Normal Weight (ISNW/IRNW) and Insulin-Sensitive/Insulin-Resistant Obesity (ISO/IRO). Results: The ISO phenotype frequency was 24.2%, with a higher prevalence in the 40–60 years age group (47.0%) and in men (44.9%), while the prevalence of IRNW was 7.0%, predominating in women (61.8%). Participants with IRNW had a more altered glycoregulation profile (fasting and 2 h OGTT blood glucose, prediabetes, and hyperinsulinism), hypercholesterolemia, and adiposity indices (ABSI) than those with ISNW, but comparable to those with IRO. Participants with ISO had a more favorable glycoregulation profile, lipid profile, adipocytokines, and adiposity indices than those with IRO. IRNW had higher odds of being associated with prediabetes (OR 10.75; p < 0.001) than ISNW, while younger age, CUN-BAE, and ABSI were independently associated with both ISO and IRNW phenotypes. Conclusions: The IRNW phenotype should be actively evaluated to intervene on the cardiometabolic risk, while further studies are needed to confirm the sustainability of the favorable cardiometabolic profile of the ISO phenotype.

## Linked entities

- **Genes:** CNR1 (cannabinoid receptor 1) [NCBI Gene 1268]
- **Diseases:** obesity (MONDO:0011122), prediabetes (MONDO:0006920)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, CNR1 (cannabinoid receptor 1) [NCBI Gene 1268] {aka CANN6, CB-R, CB1, CB1A, CB1K5, CB1R}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}
- **Diseases:** dyslipidemia (MESH:D050171), metabolic disturbances (MESH:D024821), hyperglycemia (MESH:D006943), inflammation (MESH:D007249), injury to (MESH:D014947), Prediabetes (MESH:D011236), Diabetes (MESH:D003920), overweight (MESH:D050177), Obese (MESH:D009765), hypo-HDL cholesterolemia (MESH:D052456), gestational diabetes (MESH:D016640), glycoregulation disorders (MESH:D009358), hypoadiponectinemia (MESH:C567258), metabolic disease (MESH:D008659), Atherosclerosis (MESH:D050197), hyperinsulinemia (MESH:D006946), hypertension (MESH:D006973), insulin secretory deficit (MESH:D008579), excess (MESH:D006970), Insulin resistance (MESH:D007333), hyper-LDL cholesterolemia (MESH:D006938), leptin resistance (OMIM:614962), cardiovascular disease (MESH:D002318), type 1 diabetes (MESH:D003922), systemic (MESH:D015619), Adiposity (MESH:D018205), impaired kidney function (MESH:D007674), Hypercholesterolemia (MESH:D006937), type 2 diabetes (MESH:D003924), Hypertriglyceridemia (MESH:D015228), Abdominal obesity (MESH:D056128)
- **Chemicals:** TC (MESH:D013667), triglycerides (MESH:D014280), cholesterol (MESH:D002784), TG (MESH:D013866), IRO (-), endocannabinoid (MESH:D063388), lipid (MESH:D008055), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs806368, 4895 C/T, rs806381, rs10485170, rs754387, G1359A, rs12720071, rs6454674

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12943138/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12943138/full.md

---
Source: https://tomesphere.com/paper/PMC12943138